Modality
Bispecific Ab
MOA
FGFRi
Target
KRASG12C
Pathway
mTOR
Ewing SarcomaCervical Ca
Development Pipeline
Preclinical
Feb 2024
→ Dec 2030
PreclinicalCurrent
NCT08935535
2,320 pts·Ewing Sarcoma
2024-02→2030-12·Active
2,320 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-12-154.7y awayInterim· Ewing Sarcoma
Trial Timeline
2024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
Preclinical
Active
Catalysts
Interim
2030-12-15 · 4.7y away
Ewing Sarcoma
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08935535 | Preclinical | Ewing Sarcoma | Active | 2320 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| VRT-1891 | Vertex Pharma | Phase 1 | KRASG12C | |
| Pemitapinarof | BeiGene | Approved | KRASG12C | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 |